SPPI - スペクトラム・ファ―マス―ティカルズ （Spectrum Pharmaceuticals Inc.） スペクトラム・ファ―マス―ティカルズSPPIのチャート
SPPIの企業情報
| symbol | SPPI |
|---|---|
| 会社名 | Spectrum Pharmaceuticals Inc （スペクトラム・ファ―マス―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 スペクトラム・ファーマシューティカルズ(Spectrum Pharmaceuticals Inc.)はバイオ技術会社である。同社は腫瘍学及び血液学の医薬品製品セグメントの開発・商品化を通じて営業している。同社には、癌の各タイプに対応する商業ステージと開発ステージからなる製品ポートフォリオがある。同社は非ホジキンリンパ腫（NHL）、進行性転移性結腸直腸癌（mCRC）、急性リンパ芽球性白血病（ALL）および多発性骨髄腫（MM）を含む各タイプの癌を対象とする6つの承認された腫瘍/血液製剤製品がある。また、化学療法誘発性好中球減少症のROLONTIS、非筋肉浸潤性膀胱癌（NMIBC）患者の膀胱腫瘍の経尿道的切除後の即時膀胱内注入のためのQAPZOLA、及び乳癌と肺癌を含む広範囲の固形腫瘍を有する患者の治療に使用される汎ヒト上皮増殖因子受容体（HER）阻害剤であるPOZIOTINIBを含む中期～後期段階で3つの薬剤を開発する。 スペクトラム・ファ―マス―ティカルズは米国の製薬会社。腫瘍と血液がん分野に抗がん剤に焦点を置き、大腸がん、濾胞非ホジキンリンパ腫、末梢T細胞リンパ腫、リンパ性白血病の抗がん剤を製造、販売。また、多発性骨髄腫と非筋層浸潤性膀胱がんの治療薬を開発中。製品は米国、欧州、日本で販売される。 Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. |
| 本社所在地 | 11500 South Eastern Avenue Suite 240 Henderson NV 89052 USA |
| 代表者氏名 | Stuart Mitchell Krassner スチュアート・ミッチェル・クラースナー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 702-835-6300 |
| 設立年月日 | 32112 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 215人 |
| url | www.sppirx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sppi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -88.65300 |
| 終値（lastsale） | 15.74 |
| 時価総額（marketcap） | 1667792110.12 |
| 時価総額 | 時価総額（百万ドル） 1541.701 |
| 売上高 | 売上高（百万ドル） 119.62800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1311.47 |
| 当期純利益 | 当期純利益（百万ドル） -10.98500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Spectrum Pharmaceuticals Inc. revenues decreased 14% to $54.7M. Net loss decreased 95% to $2.1M. Revenues reflect Product sales net decrease of 9% to $51.9M License fees and service revenue decrease of 56% to $2.8M. Lower net loss reflects Other expense increase from $650K to $58.5M (income) Interest Exp-Net of Capitalized Interest decrease of 62% to $1.8M (expense). |
SPPIのテクニカル分析
SPPIのニュース
Spectrum Pharma: Q1 Earnings Insights 2023/05/09 14:03:55 Benzinga
Spectrum Pharma (NASDAQ: SPPI ) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Spectrum Pharma beat estimated earnings by 66.67%, reporting an … Full story available on Benzinga.com
Spectrum Pharmaceuticals rises as co. says its Q1 net sales up 54% Q/Q 2023/05/09 13:12:37 Seeking Alpha
Spectrum Pharmaceuticals (SPPI) rose ~10% Tuesday pre-market after the biopharmaceutical company said its Q1 net sales increased by 54% on a quarterly basis.
Assertio Holdings, Inc.: Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook 2023/05/09 11:18:00 Finanz Nachrichten
Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum Pharmaceuticals in All St…
Spectrum Pharma: Q1 Earnings Snapshot 2023/05/09 11:15:53 WTOP
BOSTON (AP) — BOSTON (AP) — Spectrum Pharmaceuticals Inc. (SPPI) on Tuesday reported a loss of $5 million in its…
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update 2023/05/09 11:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update. First Quarter 2023 and Recent Business Update Net sales for Q1 2023 totaled $15.6 million, an increase of 54% compared to Q4 2022. 172 targeted accounts purchased ROLVEDON™ (eflapegrastim-xnst) Injection during the
Is Spectrum Pharmaceuticals Inc. (SPPI) a opportunity to investors? 2023/02/06 16:32:00 US Post News
The share price of Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) rose to $0.81 per share on Friday from $0.81. While Spectrum Pharmaceuticals Inc. has overperformed by 0.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SPPI rose by 3.15%, with highs and lows ranging from $1.57 to $0.31, […]
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) Has Succeeded In Generating Interest In 2023, The Stock Is Up 119.81% Year-To-Date 2023/02/04 16:30:00 Marketing Sentinel
Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)’s traded shares stood at 1.95 million during the last session, with the company’s beta value hitting 2.13. At the close of trading, the stock’s price was $0.81, to imply an increase of 0.52% or $0.0 in intraday trading. The SPPI share’s 52-week high remains $1.57, putting it -93.83% down since that … Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) Has Succeeded In Generating Interest In 2023, The Stock Is Up 119.81% Year-To-Date Read More »
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Spectrum Pharmaceuticals, Inc. (SPPI) Investors of Class Action and to Actively Participate 2023/02/03 16:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Spectrum common stock between December 6, 2021 through September 22, 2022, inclusive (the “Class Period”). Such investors are encouraged to join this case by vi
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm 2023/02/03 13:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $SPPI #SPPI--The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm 2023/02/02 13:30:00 Business Wire
The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Bluebird bio Seeks Back-to-Back Nods, ''Go'' or ''No-Go'' For Revance''s Botox Rival, Amylyx'' Twin Hurdles And More: September''s Key PDUFA Catalysts Biotech Investors Must Know 2022/08/31 18:52:35 Benzinga
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. New molecular entity approvals drew a blank in August. NMEs are those active moieties that have not been previously approved by the FDA. This should be a cause of concern, as NME approvals are considered a measure of innovation in drug research. The fortunate ones that could take their drugs past the finish line included bluebird bio, Inc. (NASDAQ: BLUE ), Johnson & Johnson (NYSE: JNJ ), and Axsome Therapeutics, Inc. (NASDAQ: AXSM ). ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD ) faced rejection for expanding the label of its Nuplazid to be able to treat Alzheimer’s disease psychosis. CorMedix, Inc.’s (NASDAQ: CRMD ) defencath application was shot down by the FDA for a second time. The review period for Amicus Therapeutics, Inc.’s (NASDAQ: FOLD ) Pompe disease treatment was extended. The Prescription Drug User Fee Act, or PDUFA, date is the period by which the FDA is required to rule on an application submitted by a sponsor company.
SPECTRUM PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Spectrum Pharmaceuticals, Inc. - SPPI 2022/08/27 02:50:00 Kwhen Finance
Spectrum Pharmaceuticals: Revisiting This ''Soap Opera'' (NASDAQ:SPPI) 2022/08/21 09:46:56 Seeking Alpha
SPPI focuses on developing and commercializing novel and targeted drug products with a primary focus in oncology. Read more to see the full investment analysis.
Spectrum Pharmaceuticals (SPPI) Q2 2022 Earnings Call Transcript 2022/08/12 07:30:47 The Motley Fool
SPPI earnings call for the period ending June 30, 2022.
Spectrum Pharma rises 9% after FDA completes re-inspection of manufacturing facility for eflapegrastim drug 2022/08/11 16:52:10 Seeking Alpha
Spectrum Pharma (SPPI) is trading ~9% higher after the company said the U.S. Food and Drug Administration completes re-inspection of drug substance manufacturing facility for…